Single-Use Bioreactors Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024-2030)

Single-Use Bioreactors Market Size

Single-Use Bioreactors Market Analysis

On the basis of product type, the system category leads the market, accounting for a revenue share of 55% in 2022. This is attributable to the extensive utilization of such systems in biopharmaceutical manufacturing facilities requiring a high yield of products. Additionally, such systems are economical, versatile, and possess large-scale production capabilities. Moreover, there is a surging need for rapid development of biotherapeutics, such as antibodies, hormones, vaccines, and enzymes, in large quantities, which can be produced in such bioreactors. Therefore, all these factors are propelling the growth of the market in this category.

On the basis of the type segment, stirred-tank bioreactors accounted for the largest revenue share, of 45%, in 2022. This is attributable to numerous advantages offered by them such as low operating costs, good fluid mixing ability and oxygen transfer, and easy scale-up.

Whereas, the wave-induced category is projected to witness significant growth during the forecast period. This can be attributed to the manufacturing developments in this type of system. Furthermore, advantages like flexible configuration of accessories, convenient handling, low costs, and long-life cycle are posing a positive impact on the market in this category.

On the basis of the cell type segment, the mammalian cells category dominated the market in 2022. This is because these cells are widely used for the development of recombinant proteins and biopharmaceutical therapies. According to a study, it has been observed that a large amount of biopharmaceutical candidates is developed using the mammalian cell culture.

Whereas, the yeast cells category is projected to display significant growth during the forecast period. This can be because these cells offer advantages in the production of therapeutic recombinants and aid in serving as heterologous and homologous hosts for biopharmaceutical synthesis. Furthermore, advantages offered by them such as easy gene manipulation, significant growth on affordable media, and ease of addition of post-translational alterations of eukaryotes have gained the attention of several research organizations and researchers to utilize such cells in clinical settings.

On the basis of molecule type, the vaccines category accounted for the largest revenue share in 2022. This is accredited to the upsurge in infectious diseases over the last few years. The rise in contagious ailments has led to a surge in the mass production of vaccines for prophylaxis and therapeutic purposes. Additionally, the outbreak of the COVID-19 pandemic led many biopharmaceutical firms to manufacture vaccines rapidly and in large amounts. This led them to adopt single-use bioreactors, as they provide simple installation, require less capital investments, and eliminate validation issues and others. All these benefits offered by the system pose a positive impact on the single-use bioreactors market.

Furthermore, the monoclonal antibodies category holds a substantial share as well in the industry. This is accredited to the growing prevalence of severe chronic ailments and the rising use of mAbs for the treatment of the same. mAbs are obtained from biological sources and are used to produce antibodies for the treatment of diseases like blood cancer and autoimmune ailments. Thus, due to several benefits, the requirement for monoclonal antibodies is also on the rise. Moreover, according to a study, it was observed that the production, efficiency, and performance of monoclonal antibodies can be accelerated with the use of single-use bioreactors.

Additionally, the surging number of collaborations among top players, the rising research and development initiatives, the increasing demand for therapeutics, and the growing cases of ailments are contributing to the market growth in this category. For instance, in January 2022, an Australian firm HaemaLogiX collaborated with a Swiss pharmaceutical manufacturing company Lonza. As per the agreement, Lonza would manufacture a drug substance of HeamLogiX lead drug molecule for multiple myeloma.

In addition, the gene-modified cells category is expected to display a high growth rate during the forecast period. This can be attributed to the advancements in the field of genetics and genomics, and the surging adoption of cell and gene therapies for the treatment of several serious genetic disorders like sickle cell anemia, hemophilia, cystic fibrosis, and muscular dystrophy.

On the basis of the usage type segment, the lab-scale production category leads the single-use bioreactors market. This is because the biopharmaceutical industry requires the frequent utilization of bioreactors for various clinical and preclinical research purposes. Additionally, the growing acceptance and advancements in single-use technologies will further boost the industry expansion in this category.

Whereas, the large-scale production category is expected to witness a high growth rate in the coming years. This can be due to the rising demand for biopharmaceutical commodities for commercial purposes and the increasing production capacities to meet these demands.

Geographical Analysis

Globally, North America holds the largest market share. This is accredited to the growing prevalence of chronic ailments like diabetes, the presence of top players and robust healthcare facilities, technological advancements in this field, and robust research and development initiatives such as availability and accessibility to research funding, in the region.

In North America, the U.S. is significantly contributing to the market expansion. This is credited to the growing adoption of cutting-edge technologies, the rising public awareness for disease prevention, strong government support, and advanced healthcare facilities in the country.

Furthermore, the European market is projected to display significant growth during the forecast period. This can be accredited to the presence of key industry players and major research institutions operating in the region. Additionally, the growing expenditure on healthcare systems and the establishment of universal healthcare systems in several nations have significantly boosted the demand for single-use systems in the region.

Germany is majorly contributing to the regional market. This is because of the surging awareness among people to get early or preventive treatment for a disease, the growing older population base, the rising adoption of technology-based solutions, and the increasing medical budget in the country. Whereas, the French market is expected to display substantial growth in the upcoming years. This can be accredited to the surging prevalence of ailments, the improving medical facilities, and the growing biotechnology and pharmaceutical sectors in the nation.

Report Breakdown

Based on Product Type

• Systems, By Capacity
  • Up to 10 L
  • 11– 100 L
  • 101 – 500 L
  • 501–1500 L
  • Above 1500 L
• Media Bags, By Type
  • 2D
  • 3D
• Assemblies

Based on Type

• Wave-Induced
• Stirred-Tank

Based on Cell Type

• Mammalian Cells
• Yeast Cells
• Bacterial Cells

Based on Molecule Type

• Monoclonal Antibodies
• Gene-Modified Cells
• Vaccines
• Stem Cells

Based on Application

• Research & Development
• Process Development
• Bioproduction

Based on Usage Type

• Lab-Scale Production
• Pilot-Scale Production
• Large-Scale Production

Based on End User

• CROs & CMOs
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Top Single-Use Bioreactors Companies